What is the KLOW peptide blend, and what does the search ask?
A GLOW vial drops KPV and keeps the other three. Neither is an approved product, and neither appears in PinPoint's library as a single entry; each of the four components does, with its own research status, half-life input and package example [6].
Searches for klow peptide dosing assume a blend has one dose. It does not. A blend vial has one liquid volume and several component amounts printed on its label, and every draw delivers a fixed fraction of each. The meaningful questions are therefore what each compound is, what its evidence covers, and how to keep the components visible in a record instead of collapsing them into one line called KLOW.
What do the sources say about each KLOW component?
KPV is the tripeptide lysine-proline-valine. Its cited study found that it enters intestinal and immune cells through the PepT1 transporter and dampened inflammatory signaling in cell culture; added to drinking water, it reduced the incidence of chemically induced colitis in mice [1]. The library lists KPV as research use only [6].
GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine. The cited 2015 review describes GHK as a naturally occurring human peptide and surveys gene-expression and skin-regeneration research, much of it in cells, animals and topical cosmetic use [2]. The library labels it limited human research with a low-confidence half-hour input [6].
BPC-157 is a 15-amino-acid synthetic peptide. Its library source is a 2022 pharmacokinetics study in rats and dogs that measured distribution, metabolism and excretion after injection [3]. The library uses the resulting quarter-hour half-life as a low-confidence estimate for people [6].
TB-500 is not full-length thymosin beta 4. A 2012 analysis identified an acetylated seven-amino-acid fragment of thymosin beta 4 in a TB-500 product [4], while the human safety study in the library gave the full 43-amino-acid protein intravenously to healthy volunteers [5]. Those are different molecules, and the library marks TB-500 as primarily preclinical [6].
| Compound | Status | Half-life input | Package example |
|---|---|---|---|
| KPV | Research use only, estimated model data | 0.5 h | 5 mg (vendor listing) |
| GHK-Cu | Limited human research, estimated model data | 0.5 h | 50 mg (vendor listing) |
| BPC-157 | Limited human research, estimated model data | 0.25 h | 5 mg (vendor listing) |
| TB-500 | Primarily preclinical, estimated model data | 3 h | 10 mg (vendor listing) |
How is a KLOW blend measured and converted to units?
A blend vial behaves like any powder vial, except that the arithmetic runs once per component. Each component's concentration is its labeled milligrams divided by the same final volume, and every draw carries the same fraction of each component's total [7].
Because blend labels vary, the worked example uses fractions rather than invented amounts. In a 2 mL final volume, 10 U-100 units is 0.1 mL, which is one twentieth of the liquid, so the draw holds one twentieth of whatever milligrams the label lists for each of the four peptides [7]. Read the four amounts from the vial label, divide each by 20, and the result is four separate entries. The peptide calculator handles each component as its own vial-and-volume pair.
The arithmetic also explains why a blend cannot be adjusted for one component. Drawing more to reach a larger KPV amount raises GHK-Cu, BPC-157 and TB-500 by the same proportion. Separate vials, each run through the BPC-157 calculator or the TB-500 calculator, are the only way to set components independently.
How do people log a KLOW blend in PinPoint?
PinPoint's library lists KPV, GHK-Cu, BPC-157 and TB-500 individually, [6]. A blend injection can therefore be recorded by hand as one entry per compound, using the compound, dose, site and pain level fields, with the milligrams that draw delivered [8][7]. Logged that way, the history answers questions a single KLOW line cannot, such as how much TB-500 was recorded across a month.
Each compound then keeps its own modeled line on the Home curve, drawn from its own half-life input, and reminders follow the day and time set [8]. The curves are mathematical visualizations of population averages and do not account for individual variation [8]. The milligrams in each entry come from the label arithmetic above, because one vial supplies all four [7].
Get PinPoint on the App StoreWhat do people ask about the KLOW blend?
- What is in KLOW peptide?
- KLOW blends combine KPV, GHK-Cu, BPC-157 and TB-500 in one vial. GLOW blends combine GHK-Cu, BPC-157 and TB-500 without KPV. Component amounts differ by vendor and are read from the vial label.
- Is there a KLOW peptide dosing study?
- No study of the blend appears in the library's sources. Each component has its own source, mostly cell or animal research, and none of them tested the four together.
- How many units of a KLOW blend equal one twentieth of the vial?
- In a 2 mL final volume, 10 U-100 units is 0.1 mL, which is one twentieth of the liquid and so one twentieth of each component. In 1 mL, the same fraction would be 5 units.
- Can a peptide tracker log a blend?
- PinPoint's library has no blend entry, but it lists each component individually, so a blend can be recorded by hand as one entry per component. That keeps each compound's total and modeled curve visible instead of hiding them under one blend name.
Where do these facts come from?
Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.
- PepT1-mediated KPV uptake and intestinal inflammation, 2008Gastroenterology, 2008. Cell and mouse colitis models.Retrieved 2026-10-05 · study
- GHK peptide as a modulator of skin regeneration pathways, 2015Biomed Res Int, 2015 (PubMed 26236730). Review of GHK and its copper complex.Retrieved 2026-10-05 · review
- Pharmacokinetics of BPC-157 in rats and dogs, 2022Front Pharmacol, 2022 (PubMed 36588717). Preclinical pharmacokinetics, distribution, metabolism and excretion.Retrieved 2026-10-05 · study
- Characterisation of the thymosin beta 4 fragment found in TB-500, 2012Drug Test Anal, 2012. Identity of the N-terminal acetylated 17-23 fragment.Retrieved 2026-10-05 · study
- Intravenous thymosin beta 4 single and multiple dose study in healthy volunteers, 2010Ann N Y Acad Sci, 2010. Phase 1 safety and pharmacokinetics of full-length thymosin beta 4.Retrieved 2026-10-05 · study
- PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
- Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description